AbCellera (ABCL) Q2 FY26 earnings call

AbCellera reported a challenging revenue quarter but highlighted significant progress in its clinical pipeline, particularly with the ABCL635 Phase II study nearing a top-line data readout. The company also strengthened its T cell engager platform through new collaborations with Vertex and Jazz Pharmaceuticals, securing substantial upfront payments and potential downstream value, while maintaining a robust liquidity position to fund future pipeline investments.